{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T05:26:52Z","timestamp":1767245212489,"version":"3.37.3"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T00:00:00Z","timestamp":1472860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"German Federal Ministry of Education (BMBF) \u201cCLIOMMICS\u201d and \u201cCAMPSIMM\u201d","award":["01ZX1309","01ES1103"],"award-info":[{"award-number":["01ZX1309","01ES1103"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SFB\/TRR79"],"award-info":[{"award-number":["SFB\/TRR79"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dietmar Hopp Stiftung \u201cHeidelberger Konzept zur Optimierung der Diagnostik und Therapie des Multiplen Myeloms\u201d, and the 7th EU-framework program \u201cOverMyR\u201d"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:p>Deletion 17p13, del(17p), is associated with poor outcome in myeloma but some patients show long\u2010term survival. With the current study we intended to identify factors impacting outcome of such high risk patients. We analyzed 110 newly diagnosed, symptomatic patients with del(17p) detected by fluorescence <jats:italic>in situ<\/jats:italic> hybridization (FISH) in CD138\u2010purified myeloma cells to identify prognostic factors for survival. Age &gt;65 years, ISS III, and elevated LDH negatively impacted survival. Patients with subclonal (10\u201360% of plasma cells) del(17p) had longer progression\u2010free survival (PFS) than patients with del(17p) in &gt;60% of plasma cells (26 vs. 19 months, <jats:italic>P<\/jats:italic>\u2009=\u20090.03). Additional gain of 1q21 was associated with shorter PFS (17 vs. 25 months, <jats:italic>P<\/jats:italic>\u2009=\u20090.01). Hyperdiploidy did not ameliorate impact of del(17p), but gain 19q13 predicted longer PFS (30 vs. 18 months, <jats:italic>P<\/jats:italic>\u2009=\u20090.01) and overall survival (50 vs. 29 months, <jats:italic>P<\/jats:italic>\u2009=\u20090.01). Multivariate analysis in transplant eligible patients (\u226465 years) revealed better survival for patients treated with upfront autologous transplantation (hazard ratio, [95% confidence interval]: 0.15 [0.04, 0.58], <jats:italic>P<\/jats:italic>\u2009=\u20090.006). Application of maintenance therapy was associated with better survival in transplant\u2010eligible patients (0.30 [0.09, 0.99], <jats:italic>P<\/jats:italic>\u2009=\u20090.05). We demonstrate heterogeneous outcome of patients with del(17p) according to baseline characteristics and treatment. 19q13 should be included in routine FISH panel, since gains were associated with better survival. Am. J. Hematol. 91:E473\u2013E477, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24533","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T15:36:43Z","timestamp":1470843403000},"source":"Crossref","is-referenced-by-count":27,"title":["Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma"],"prefix":"10.1002","volume":"91","author":[{"given":"Maximilian","family":"Merz","sequence":"first","affiliation":[{"name":"Medizinische Klinik V, University Hospital Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[{"name":"Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, University Hospital Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, University Hospital Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-1252","authenticated-orcid":false,"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, University Hospital Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, University Hospital Heidelberg Heidelberg Germany"},{"name":"Max\u2010Eder Research Group Experimental therapies for hematologic malignancies, DKFZ Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, University Hospital Heidelberg Heidelberg Germany"},{"name":"National Center for Tumor Diseases (NCT) Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, University Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, University Hospital Heidelberg Heidelberg Germany"},{"name":"Department of Radiology German Cancer Research Center DKFZ Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.7900"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1363"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.3.802"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24487"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0329"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2576"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379164"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587964"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390658"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-584268"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.3945"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403586"},{"key":"e_1_2_7_17_1","first-page":"e328","article-title":"Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: Use of \u201cprogression\u2010free survival 2\u201d as a clinical trial end\u2010point","volume":"100","author":"Dimopoulos MA","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2598"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-666537"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040410"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404172"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650242"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4046"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.287"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24533","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:37:12Z","timestamp":1695490632000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,3]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/ajh.24533"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24533","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"type":"print","value":"0361-8609"},{"type":"electronic","value":"1096-8652"}],"subject":[],"published":{"date-parts":[[2016,9,3]]}}}